In step with vVARDIS, the transaction offers the privately owned scientific era corporate a valuation of greater than US$1.0 billion (€853.3 million*), a threshold continuously described in funding markets as “unicorn” standing. The monetary phrases of the transaction weren’t disclosed. The corporate’s founders and co-CEOs, Drs Haley and Goly Abivardi, will retain a considerable majority shareholding in vVARDIS.
The founders and co-CEOs of vVARDIS, Drs Goly (left) and Haley Abivardi, will retain a considerable majority shareholding following a strategic minority funding through asset control company Apollo. (Symbol: Jos Schmid)
The corporate advanced Curodont era, a non-invasive, peptide-based technique to the remedy of early carious lesions. Certainly one of its key merchandise, Curodont Restore Fluoride Plus, is recently being rolled out in the United States, the place Henry Schein is the unique distributor. Since the release of Curodont Restore Fluoride Plus in the United States in early 2024, the product has been used to regard roughly 3 million tooth, in step with vVARDIS, and it’s now in just about 20% of basic dental practices national and a few of the fastest-growing dental merchandise in the United States.
Jeremy Honeth, spouse at Apollo, stated in a press free up that Drs Haley and Goly Abivardi had pioneered “a brand new class in dental care”, subsidized through peer-reviewed medical research, and constructed vVARDIS into “a differentiated trade”. He added: “Apollo’s funding helps the corporate’s persevered enlargement in key markets throughout the United States and Europe, bringing this restorative remedy to extra practices and sufferers international.”
“Curodont fills a longstanding hole in dentistry: when prevention fails, dentists now have a snappy, easy-to-use non-invasive remedy. The speedy adoption of Curodont displays the urgency of that unmet want,” stated Dr Haley Abivardi. “Apollo’s funding will fortify our industrial basis in the United States and Europe and can permit us to scale this environmentally sustainable era throughout markets,” she mentioned.
Dr Goly Abivardi emphasized: “Our undertaking is to convey a scientific, science-driven technique to dentistry. The usage of peptide-containing formulations, our non-invasive era is an leading edge remedy designed to regard caries with out drilling and with out polymer fabrics. Apollo’s funding reinforces our management in generative dentistry and advances the way forward for oral science.”
The Apollo funding follows two previous financing bulletins ultimate yr. In February 2025, vVARDIS secured US$35 million from world healthcare investor OrbiMed to fortify expansion tasks, together with the additional commercialisation of Curodont. In July 2025, the corporate raised an extra US$50 million from OrbiMed.
